Key result
Coronary heart disease linked to significantly elevated CD40/CD40L and CD134/CD134L expression.
Why the study?
The potential role of costimulatory molecules CD40/CD40L and CD134/CD134L in the development of coronary heart disease was not well defined.
Case-Control (n=354)
No
p-value: p=<.05
CD40/CD40L and CD134/CD134L are significantly upregulated in patients with coronary heart disease and correlate with disease severity, suggesting a role in its immune-mediated pathophysiology.
The aim of the study was to evaluate the potential role of CD40/CD40 ligand (CD40L) and CD134/CD134 ligand (CD134L) in the development of coronary heart disease (CHD) via the performance of a case-control study.The research objects were 234 cases of CHD patients and 120 cases of well-matched normal controls. Following the separation of peripheral blood mononuclear cells (PBMCs), real-time quantitative PCR (qRT-PCR), Western blot, immunohistochemistry, and flow cytometry were applied for the detection of mRNA levels and expression levels of CD40/CD40L and CD134/CD134L; meanwhile, intercellular adhesion molecule-1 (ICAM-1) and Fas protein mRNA levels were detected using qRT-PCR.There was no statistical difference in the comparison of baseline characteristics between groups, indicating comparability between groups. qRT-PCR and Western blot analysis indicated that CD40/CD40L and CD134/CD134L mRNA and protein expression levels were all increased in the CHD group than those in the control group. Flow cytometry further confirmed the similar tendency. Meanwhile, ICAM-1 and Fas protein mRNA levels were elevated in the CHD group and positively correlated with the above parameters. Furthermore, CD40/CD40L expression rates were negatively correlated with gender and different types of CHD. Meanwhile, CD134/CD134L expressions were also higher in male patients, in patients with family history, previous history of hypertension, diabetes, and cerebrovascular diseases.CD40/CD40L and CD134/CD134L are increased and may have potential correlation with clinical pathological features of patients with CHD. Further in-depth exploration of costimulatory molecules for CHD guidance as well as intrinsic mechanisms are needed combined with in vivo and in vitro experiments.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2017) conducted a case-control in Coronary heart disease (n=354). CD40/CD40L and CD134/CD134L expression vs. Normal controls was evaluated on CD40/CD40L and CD134/CD134L mRNA and protein expression levels (p=<.05). CD40/CD40L and CD134/CD134L mRNA and protein expression levels were significantly increased in patients with coronary heart disease compared to normal controls (P < .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: